Exenatide matching placebo

DRUG2 trials

Sponsors

AstraZeneca, Medical University of Vienna

Conditions

Diabetes MellitusSteatosis, LiverType2 Diabetes

Phase 3

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

CompletedNCT02229383

AstraZenecaDiabetes Mellitus

Start: 2014-09-06End: 2016-08-29Updated: 2019-01-08

Phase 4

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

CompletedNCT03007329

Medical University of ViennaSteatosis, Liver, Type2 Diabetes

Start: 2017-03-08End: 2020-01-16Updated: 2022-04-15

Related Papers

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease

Diabetes Therapy2020-04-189 citations

Wirksamkeit und Verträglichkeit von Depot-Exenatide gegenüber Placebo als Add-on zu Insulin glargin bei Typ-2-Diabetes-Patienten mit unzureichender glykämischer Kontrolle unter Basalinsulin: Duration-7-Studie

Diabetologie und Stoffwechsel2018-04-01

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.

2018-03-2549 citations